Eleftha Injection (375mg) is a targeted therapy medication that contains Trastuzumab, a monoclonal antibody specifically designed to treat certain types of breast cancer and gastric cancer that overexpress the HER2 protein. This innovative drug works by binding to the HER2 receptors on the surface of cancer cells, inhibiting their growth and proliferation. Eleftha Injection is typically administered intravenously and is often used in conjunction with other chemotherapy agents to enhance treatment efficacy. The composition of Eleftha includes Trastuzumab as the active ingredient, which is crucial for its therapeutic action. This medication is a vital option for patients with HER2-positive cancers, providing a targeted approach that can lead to improved outcomes and quality of life.